



BIOSENSORS  
INTERNATIONAL

NEWS RELEASE

## **BIOSENSORS AND TERUMO AMEND TERMS OF LICENSE AGREEMENT**

Singapore, 22 April 2008. Biosensors International Group Ltd (“Biosensors”, “Company”, Bloomberg: BIG SP) today announced that its subsidiary, Biosensors Europe SA (“BESA”), has signed a modification to the license agreement with Terumo Corporation, amending the original agreement entered into in October 2003. Under the original agreement, Terumo was granted a license to develop, manufacture, market and sell drug-eluting stent systems incorporating Biosensors’ BioMatrix<sup>®</sup> drug-eluting stent technologies. Terumo’s rights to market and sell their recently approved NOBORI<sup>™1</sup> drug-eluting stent system are exclusive in Japan and non-exclusive elsewhere, except the United States where Biosensors retains all rights. As previously disclosed, Terumo has paid Biosensors’ entities a total of US\$14.0 million in milestone payments and is required to share future revenues with BESA over the term of the agreement, which is five years after initial launch of the NOBORI drug-eluting stent.

Under the terms of the revised agreement, Terumo has agreed to pay BESA US\$40 million in exchange for a reduction of the revenue sharing provisions applicable to sales of the NOBORI stent outside of Japan. The revised agreement also clarifies other operational and development aspects of the companies’ relationship going forward. The US\$40 million payment will be paid within 30 days and those revenues will be recognized by Biosensors over the 5- year term of the agreement.

Mr. Yoh Chie Lu, Chairman of Biosensors said, “Terumo is a great partner and we are very excited that BioMatrix and NOBORI are now available to patients and physicians in many parts of the world. This modification to our original agreement represents another step in our long-term strategic relationship, as together we can make a major impact in cardiac care and in the drug-eluting stent market. We will continue to work closely together in many ways to strengthen our respective technologies for future growth.”

Mr. Mike Kleine, President and CEO of Biosensors added, “This amended agreement provides significant benefits to Biosensors and Terumo. Biosensors can monetize a portion of its future revenues to fund current growth initiatives and we will continue to participate in the success of the Terumo stent program. With this reduction in the revenue sharing arrangement, Terumo is now in a stronger position to increase their sales of the NOBORI stent, as this product will now have a much better contribution to their operating results. This US\$ 40 million payment is a strong indication of Terumo’s belief in the strength of this technology platform and their ability to generate significant sales over the term of the agreement.”

1 - The NOBORI drug-eluting stent utilizes Biosensors’ core drug-eluting stent technology including the S-Stent, biodegradable polymer and unique anti-restenotic drug, Biolimus<sup>®</sup> A9 drug.

### END OF RELEASE ###

## **Media Relations & Investor Relations Biosensors International Group**

Mr. Loh Chee Mun  
Senior Vice President  
Tel: (65) 6213 5708  
Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

## **Media Relations / Investor Relations Firm United States**

Allen & Caron Inc.  
Mr. Matt Clawson  
Executive Vice President, Investor Relations  
Tel: (1) 949 474 4300  
Email: [matt@allencaron.com](mailto:matt@allencaron.com)

## **About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drug-eluting stent programs, BioMatrix<sup>®</sup>, Axxion<sup>™</sup>, and BioFreedom<sup>™</sup>, a completely polymer-free drug-eluting stent.

For more information, please visit [www.biosensors.com](http://www.biosensors.com).

## **About BioMatrix<sup>®</sup>**

BioMatrix<sup>®</sup> offers the unique combination of an innovative anti-restenotic drug, Biolimus A9<sup>®</sup>, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability. Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately leaving in place a biocompatible stent surface.

Biosensors will initiate several post marketing surveillance registries on the BioMatrix stent in April collecting data on over 5000 patients with five year follow-up. For more information, please visit [www.biomatrix.com](http://www.biomatrix.com).

## **Forward-Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*